Graft Versus Host Disease News and Research

Latest Graft Versus Host Disease News and Research

Allo-HSCT Non-Relapse Related Mortality Reduction Revealed

A reduction in the risks of infection- and organ failure-related death has driven an improvement in non-relapse mortality among recipients of allogeneic haematopoietic stem cell transplantation, Japanese research suggests.

17 Feb 2016

Anthony Nolan introduces new tissue typing method that could revolutionise stem cell transplantation

Anthony Nolan has today launched a new tissue typing method that could significantly improve stem cell transplant outcomes.

8 Jan 2016

Study shows promise for cord blood-derived natural killer cells in multiple myeloma patients

A first-in-human Phase I study of multiple myeloma patients combined expanded cord blood-derived natural killer cells with transplantation of a patient's own stem cells and high-dose chemotherapy with little or none of the side effects seen with current treatments.

8 Dec 2015

Research shows significant step toward improving outcomes, reducing treatment burden for SCD patients

Emerging therapies and promising new insights in the treatment of sickle cell disease represent a significant step toward improving outcomes and reducing the treatment burden for affected children and adults. Studies reporting these advances will be presented today at the 57th American Society of Hematology Annual Meeting and Exposition.

7 Dec 2015

Experimental gene therapy may improve health outcomes for patients with some forms of blood disorders

New research adds to a growing body of evidence that gene therapy, an experimental technique that involves correcting or replacing a person's mutated or malfunctioning genes, may improve health outcomes for patients with inherited bleeding and immune disorders as well as some forms of blood cancer.

7 Dec 2015

Researchers discover drug target and genetic pathway for graft-versus-host disease

A Seattle Children's Research Institute lab has discovered a genetic pathway that can be targeted with existing drugs to prevent graft-versus-host disease (GVHD), a common and deadly complication of bone marrow transplants.

30 Nov 2015

Six-month markers predict long-term cGVHD outcomes

Researchers have identified measures early in the course of chronic graft-versus-host disease that predict long-term prognosis in haematopoietic cell transplantation recipients.

27 Nov 2015

Half-matched donor bone marrow transplant just as good as full match, new study shows

Bone marrow transplantation is a life-saving therapy for many patients with blood cancers like leukemias and lymphomas. Currently, the gold standard blood-generating stem cells are obtained from a donor, a sibling, with a perfect match to the patient in order to minimize the chance of rejection and other complications. However, not all patients will have a perfectly matched sibling. Some cancer centers have begun to explore whether half-matched donors might work just as well.

8 Oct 2015

HLA-DPB1 regulatory region genotype predicts acute GVHD

Analysis of a HLA-DPB1 regulatory region variant has shed light on the risk of acute graft-versus-host disease in patients undergoing haematopoietic cell transplantation from an unrelated donor.

1 Oct 2015

Centenary Institute develops new therapeutic approach to prevent GVHD in blood cancer patients

Sydney’s Centenary Institute has developed a new therapeutic approach that could help to improve outcomes for patients undertaking treatment for blood cancer.

26 Aug 2015

HCT not precluded by prior second-generation TKI therapy in chronic, advanced phase CML

Allogeneic haematopoietic stem cell transplantation can be considered for chronic- and accelerated-phase chronic myeloid leukaemia patients with prior exposure to second-generation tyrosine kinase inhibitors, say Polish researchers.

17 Aug 2015

HCT not precluded by prior second-generation TKI therapy in chronic, advanced phase CML

14 Aug 2015

Mallinckrodt subsidiary to acquire Therakos for $1.325 billion

Mallinckrodt plc, a leading specialty biopharmaceutical company, and The Gores Group, a global investment firm, announced today that they have entered into a definitive agreement under which a subsidiary of Mallinckrodt will acquire Therakos, Inc. a leading immunotherapy company in a transaction valued at approximately $1.325 billion.

10 Aug 2015

New drug cures malaria in mice

A new drug acts as a roadblock for malaria, curing mice of established infection, according to a study in The Journal of Experimental Medicine. Treatment was not associated with obvious side effects, suggesting that the drug may also be safe and effective in humans.

21 Jul 2015

Massey researchers aim to develop models that can predict complications from stem cell transplantation

Researchers at VCU Massey Cancer Center's Bone Marrow Transplant Program have recently published findings from a phase 2 clinical trial that demonstrate lymphocyte recovery in related and unrelated stem cell transplant recipients generally falls into three patterns that are significantly associated with survival.

10 Jun 2015

Pharmacyclics’ Ibrutinib Phase Ib/II data show ibrutinib may be safe and effective in patients with cGVHD

Pharmacyclics LLC today announced interim results from the ongoing Phase Ib/II PCYC-1129 study suggesting that ibrutinib (IMBRUVICA) may be a safe and effective treatment for patients with chronic graft-versus-host-disease (cGVHD) who were either refractory to steroid treatment or were steroid-dependent.

1 Jun 2015

Skin Cancer Awareness Recommended For HCT Recipients

Patients who undergo haematopoietic cell transplantation should be educated on the risk of skin cancer and the need for regular self-examination, US researchers say.

29 May 2015

Chemical drug safely controls side effects associated with haploidentical stem cell transplantation

Researchers in the Center for Cell and Gene Therapy at Baylor College of Medicine, Houston Methodist and Texas Children's Hospital have found that a single dose of an otherwise harmless drug can safely control the severe and often lethal side effects associated with haploidentical stem cell transplantation.

15 May 2015

Clinical trial uses personalized cellular therapy to treat GVHD complication of bone marrow transplant

An innovative clinical trial using the science of "personalized" cellular therapy has begun enrolling children and adults suffering from graft-versus-host-disease (GVHD), a life-threatening complication of bone marrow transplantation in which donor immune lymphocytes attack the organs of the bone marrow transplant recipient.

3 Apr 2015

Transplantation conditioning choices impact on CML outcomes revealed

For chronic myeloid leukaemia patients in their first chronic phase, the optimal pretransplantation conditioning regimen may be cyclophosphamide combined with intravenous busulfan, research suggests.

17 Feb 2015

Graft Versus Host Disease News and Research

Latest Graft Versus Host Disease News and Research

Allo-HSCT Non-Relapse Related Mortality Reduction Revealed

Anthony Nolan introduces new tissue typing method that could revolutionise stem cell transplantation

Study shows promise for cord blood-derived natural killer cells in multiple myeloma patients

Research shows significant step toward improving outcomes, reducing treatment burden for SCD patients

Experimental gene therapy may improve health outcomes for patients with some forms of blood disorders

Researchers discover drug target and genetic pathway for graft-versus-host disease

Six-month markers predict long-term cGVHD outcomes

Half-matched donor bone marrow transplant just as good as full match, new study shows

HLA-DPB1 regulatory region genotype predicts acute GVHD

Centenary Institute develops new therapeutic approach to prevent GVHD in blood cancer patients

HCT not precluded by prior second-generation TKI therapy in chronic, advanced phase CML

HCT not precluded by prior second-generation TKI therapy in chronic, advanced phase CML

Mallinckrodt subsidiary to acquire Therakos for $1.325 billion

New drug cures malaria in mice

Massey researchers aim to develop models that can predict complications from stem cell transplantation

Pharmacyclics’ Ibrutinib Phase Ib/II data show ibrutinib may be safe and effective in patients with cGVHD

Skin Cancer Awareness Recommended For HCT Recipients

Chemical drug safely controls side effects associated with haploidentical stem cell transplantation

Clinical trial uses personalized cellular therapy to treat GVHD complication of bone marrow transplant

Transplantation conditioning choices impact on CML outcomes revealed

Industry Focus eBook - Pharmaceutical manufacturing (2nd edition) eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Graft Versus Host Disease News and Research

Latest Graft Versus Host Disease News and Research

Industry Focus eBook - Pharmaceutical manufacturing (2nd edition) eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Newsletters you may be interested in